Table 3.
Characteristics of the patients with alterations on the menstrual cycle, discriminated by biological applied.
| Parameter | Pfizer, N = 51 a | Sinovac, N = 53 a | Janssen, N = 33 a | Moderna, N = 15 a | AstraZeneca, N = 13 a | Others, N = 19 a |
|---|---|---|---|---|---|---|
| Age (years) | 29 (26, 35) | 27 (24, 38) | 32 (26, 36) | 27 (26, 28) | 29 (24, 34) | 22 (18, 25) |
| Weight (kg) | 59 (55, 66) | 62 (56, 68) | 62 (58, 69) | 55 (50, 62) | 65 (61, 68) | 60 (53, 62) |
| Height (m) | 1.60 (1.58, 1.65) | 1.62 (1.57, 1.67) | 1.62 (1.59, 1.69) | 1.59 (1.55, 1.68) | 1.64 (1.60, 1.66) | 1.63 (1.60, 1.65) |
| BMI | 23.19 (21.48, 24.99) | 23.50 (22.04, 25.30) | 23.73 (20.70, 25.32) | 20.81 (20.21, 23.79) | 24.17 (22.27, 26.30) | 21.78 (20.73, 24.57) |
| BMI Category | ||||||
| Normal | 39 (76%) | 38 (72%) | 23 (70%) | 14 (93%) | 9 (69%) | 14 (74%) |
| Overweight | 12 (24%) | 15 (28%) | 10 (30%) | 1 (6.7%) | 4 (31%) | 5 (26%) |
| Continent | ||||||
| South America | 43 (84%) | 48 (91%) | 30 (91%) | 11 (73%) | 8 (62%) | 18 (95%) |
| Europe | 7 (14%) | 2 (3.8%) | 1 (3.0%) | 1 (6.7%) | 2 (15%) | 0 (0%) |
| North and Central America | 1 (2.0%) | 3 (5.7%) | 2 (6.1%) | 3 (20%) | 3 (23%) | 1 (5.3%) |
| Planning | ||||||
| No | 13 (25%) | 16 (30%) | 8 (24%) | 2 (13%) | 2 (15%) | 2 (11%) |
| Yes | 38 (75%) | 37 (70%) | 25 (76%) | 13 (87%) | 11 (85%) | 17 (89%) |
| Contraceptive method | ||||||
| Periodic abstinence | 1 (2.0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Combined vaginal ring | 0 (0%) | 0 (0%) | 0 (0%) | 1 (6.7%) | 0 (0%) | 0 (0%) |
| Combined injectable contraceptives | 5 (9.8%) | 3 (5.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Combined oral contraceptives (OCs) | 6 (12%) | 11 (21%) | 4 (12%) | 4 (27%) | 2 (15%) | 6 (32%) |
| Progestin-only oral contraceptives | 2 (3.9%) | 1 (1.9%) | 1 (3.0%) | 0 (0%) | 0 (0%) | 1 (5.3%) |
| Condom | 15 (29%) | 16 (30%) | 13 (39%) | 6 (40%) | 7 (54%) | 8 (42%) |
| Intrauterine devices | 5 (9.8%) | 3 (5.7%) | 1 (3.0%) | 1 (6.7%) | 0 (0%) | 0 (0%) |
| Progestin-only implants | 2 (3.9%) | 0 (0%) | 1 (3.0%) | 0 (0%) | 1 (7.7%) | 1 (5.3%) |
| Tubal ligation | 2 (3.9%) | 2 (3.8%) | 4 (12%) | 1 (6.7%) | 0 (0%) | 0 (0%) |
| Symptothermal method | 0 (0%) | 0 (0%) | 1 (3.0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| I don’t use contraceptive methods | 13 (25%) | 16 (30%) | 8 (24%) | 2 (13%) | 2 (15%) | 2 (11%) |
| Combined contraceptive patch | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (5.3%) |
| Vasectomy | 0 (0%) | 1 (1.9%) | 0 (0%) | 0 (0%) | 1 (7.7%) | 0 (0%) |
| Complete scheme | ||||||
| No | 2 (3.9%) | 6 (11%) | 0 (0%) | 10 (67%) | 8 (62%) | 8 (42%) |
| Yes | 49 (96%) | 47 (89%) | 33 (100%) | 5 (33%) | 5 (38%) | 11 (58%) |
| Post-vaccination menstrual frequency | ||||||
| Amenorrhea | 5 (9.8%) | 7 (13%) | 1 (3.0%) | 1 (6.7%) | 1 (7.7%) | 2 (11%) |
| Infrequent | 16 (31%) | 13 (25%) | 9 (27%) | 2 (13%) | 2 (15%) | 4 (21%) |
| Normal | 19 (37%) | 28 (53%) | 13 (39%) | 7 (47%) | 6 (46%) | 7 (37%) |
| Frequent | 11 (22%) | 5 (9.4%) | 10 (30%) | 5 (33%) | 4 (31%) | 6 (32%) |
| Post-vaccination menstrual regularity | ||||||
| Amenorrhea | 3 (5.9%) | 4 (7.5%) | 0 (0%) | 1 (6.7%) | 1 (7.7%) | 2 (11%) |
| Irregular | 20 (39%) | 20 (38%) | 19 (58%) | 4 (27%) | 5 (38%) | 11 (58%) |
| Normal or regular | 28 (55%) | 29 (55%) | 14 (42%) | 10 (67%) | 7 (54%) | 6 (32%) |
| Post-vaccination menstrual duration | ||||||
| Amenorrhea | 5 (9.8%) | 5 (9.4%) | 1 (3.0%) | 1 (6.7%) | 2 (15%) | 2 (11%) |
| Normal | 33 (65%) | 38 (72%) | 22 (67%) | 10 (67%) | 7 (54%) | 10 (53%) |
| Prolonged | 13 (25%) | 10 (19%) | 10 (30%) | 4 (27%) | 4 (31%) | 7 (37%) |
| Post-vaccination menstrual volume | ||||||
| Amenorrhea | 3 (5.9%) | 4 (7.5%) | 0 (0%) | 1 (6.7%) | 2 (15%) | 2 (11%) |
| Light | 17 (33%) | 11 (21%) | 4 (12%) | 1 (6.7%) | 1 (7.7%) | 4 (21%) |
| Normal | 15 (29%) | 17 (32%) | 11 (33%) | 4 (27%) | 4 (31%) | 6 (32%) |
| Heavy | 16 (31%) | 21 (40%) | 18 (55%) | 9 (60%) | 6 (46%) | 7 (37%) |
| Change in quality of life | ||||||
| No | 27 (53%) | 24 (45%) | 10 (30%) | 5 (33%) | 7 (54%) | 8 (42%) |
| Yes | 24 (47%) | 29 (55%) | 23 (70%) | 10 (67%) | 6 (46%) | 11 (58%) |
BMI: Body Mass Index; IQR: interquartile range.
a
Median (IQR); No. (%).